Sujal Shah, President and CEO of CymaBay Therapeutics, a clinical-stage biopharmaceutical company, discusses the positive topline results from its Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. This is the first potential therapy to show promise in significantly improving markers associated with risk of disease progression and significantly reducing itch.
Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Tvardi Therapeutics, Inc. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.